Nanoen Tek나노엔텍

Nanoen Tek returned to a small profit on a trailing basis after a loss-making 2023, but margins remain thin and the share price has risen sharply.

Nanoen Tek sells in vitro diagnostic devices and lab instruments, with trailing twelve-month revenue of about ₩44.2B and operating income of about ₩1.7B to H1 2026. Net income of ₩5.9B is well above operating income, and the data does not explain the gap. The shares closed at ₩4,590 on 2026-10-23, up 36% over one year and near the middle of a 52-week range of ₩3,015 to ₩9,390.

What stands out

• Revenue rose 25.2% in 2025 to about ₩38.1B, but operating margin was only 2.9%, below the 2021 level of 14.6%.
• Trailing net income of about ₩5.9B is much larger than trailing operating income of about ₩1.7B, so non-operating items or one-offs may be involved; the data does not say.
• Trailing cash of about ₩12.3B exceeds the listed borrowings figure, which is shown as none, and liabilities are 8.7% of equity.
• The company's own DCF-based fair value estimate in the data is ₩1,717 (bear ₩1,389, bull ₩2,334), well below the current price of ₩4,590.
• Valuation is high versus the peers provided: P/E of 29.8 compared with Classys at 13.2 and Kctech at 21.5, and the stock trades at about 4x sales.

What to watch

• The next quarterly and annual results, to see whether operating margins recover from the low single digits.
• Progress of the buyback trust contract signed on 2026-09-01 and any further shareholder-return filings; the company pays no dividend.
• Foreign ownership, which is only 0.7% and rose slightly over 60 days while foreign investors were net sellers over the last 20 days.